tiprankstipranks
Trending News
More News >
Cross Country Healthcare (CCRN)
NASDAQ:CCRN
US Market

Cross Country Healthcare (CCRN) Stock Forecast & Price Target

Compare
252 Followers
See the Price Targets and Ratings of:

CCRN Analyst Ratings

Hold
8Ratings
Hold
0 Buy
8 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Cross
Country Healthcare
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CCRN Stock 12 Month Forecast

Average Price Target

$18.08
▲(37.49%Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Cross Country Healthcare in the last 3 months. The average price target is $18.08 with a high forecast of $18.61 and a low forecast of $16.50. The average price target represents a 37.49% change from the last price of $13.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","13":"$13","16":"$16","19":"$19","22":"$22"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18.61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,13,16,19,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.53,13.92076923076923,14.311538461538461,14.702307692307691,15.093076923076922,15.483846153846153,15.874615384615383,16.265384615384615,16.656153846153845,17.046923076923076,17.437692307692306,17.82846153846154,18.21923076923077,{"y":18.61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.53,13.879999999999999,14.229999999999999,14.579999999999998,14.93,15.28,15.629999999999999,15.979999999999999,16.33,16.68,17.029999999999998,17.38,17.729999999999997,{"y":18.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.53,13.758461538461537,13.986923076923077,14.215384615384615,14.443846153846154,14.672307692307692,14.90076923076923,15.12923076923077,15.357692307692307,15.586153846153845,15.814615384615385,16.043076923076924,16.271538461538462,{"y":16.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.91,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.75,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.92,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.16,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.87,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.53,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$18.61Average Price Target$18.08Lowest Price Target$16.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CCRN
TipRanks AITipRanks
Not Ranked
TipRanks
$13.5
Hold
2.66%
Upside
Reiterated
05/14/25
Cross Country Healthcare is experiencing significant financial performance challenges, with declining revenues and profitability being the most pressing concerns. The technical indicators suggest bearish momentum, adding caution to the stock's outlook. The negative P/E ratio and lack of dividend yield further highlight valuation challenges. Despite some positive corporate actions, the overall sentiment remains cautious, reflecting the need for substantial improvements in financial health and operational stability.
Oppenheimer Analyst forecast on CCRN
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
Hold
Reiterated
05/27/25
Oppenheimer Keeps Their Hold Rating on Cross Country Healthcare (CCRN)
UBS
$18.61$16.5
Hold
25.48%
Upside
Reiterated
05/13/25
Cross Country Healthcare price target lowered to $16.50 from $18.61 at UBSCross Country Healthcare price target lowered to $16.50 from $18.61 at UBS
Truist Financial Analyst forecast on CCRN
Tobey SommerTruist Financial
Truist Financial
$18.61
Hold
41.52%
Upside
Reiterated
05/08/25
Truist Financial Sticks to Their Hold Rating for Cross Country Healthcare (CCRN)
William Blair Analyst forecast on CCRN
Trevor RomeoWilliam Blair
William Blair
Hold
Reiterated
05/08/25
Cautious Hold Rating for Cross Country Healthcare Amid Revenue Decline and Market Challenges
Benchmark Co. Analyst forecast on CCRN
Bill SutherlandBenchmark Co.
Benchmark Co.
Hold
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Cross Country Healthcare (NASDAQ: CCRN) and GoodRx Holdings (NASDAQ: GDRX)
Citizens JMP
Hold
Reiterated
04/02/25
Citizens JMP reiterates Market Perform Rating on Cross Country Healthcare (CCRN)Citizens JMP analyst Constantine Davides reiterated a Market Perform rating on Cross Country Healthcare (NASDAQ: CCRN).
Barrington Analyst forecast on CCRN
Kevin SteinkeBarrington
Barrington
$18.61
Hold
41.52%
Upside
Reiterated
03/14/25
Hold Rating Maintained for Cross Country Healthcare Amidst Profitability Decline and Pending Aya Healthcare Merger
Jefferies Analyst forecast on CCRN
Jack SlevinJefferies
Jefferies
$18.61
Hold
41.52%
Upside
Reiterated
03/12/25
We expect CCRN's proposed acquisition by Aya will close in 2025.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on CCRN
TipRanks AITipRanks
Not Ranked
TipRanks
$13.5
Hold
2.66%
Upside
Reiterated
05/14/25
Cross Country Healthcare is experiencing significant financial performance challenges, with declining revenues and profitability being the most pressing concerns. The technical indicators suggest bearish momentum, adding caution to the stock's outlook. The negative P/E ratio and lack of dividend yield further highlight valuation challenges. Despite some positive corporate actions, the overall sentiment remains cautious, reflecting the need for substantial improvements in financial health and operational stability.
Oppenheimer Analyst forecast on CCRN
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
Hold
Reiterated
05/27/25
Oppenheimer Keeps Their Hold Rating on Cross Country Healthcare (CCRN)
UBS
$18.61$16.5
Hold
25.48%
Upside
Reiterated
05/13/25
Cross Country Healthcare price target lowered to $16.50 from $18.61 at UBSCross Country Healthcare price target lowered to $16.50 from $18.61 at UBS
Truist Financial Analyst forecast on CCRN
Tobey SommerTruist Financial
Truist Financial
$18.61
Hold
41.52%
Upside
Reiterated
05/08/25
Truist Financial Sticks to Their Hold Rating for Cross Country Healthcare (CCRN)
William Blair Analyst forecast on CCRN
Trevor RomeoWilliam Blair
William Blair
Hold
Reiterated
05/08/25
Cautious Hold Rating for Cross Country Healthcare Amid Revenue Decline and Market Challenges
Benchmark Co. Analyst forecast on CCRN
Bill SutherlandBenchmark Co.
Benchmark Co.
Hold
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Cross Country Healthcare (NASDAQ: CCRN) and GoodRx Holdings (NASDAQ: GDRX)
Citizens JMP
Hold
Reiterated
04/02/25
Citizens JMP reiterates Market Perform Rating on Cross Country Healthcare (CCRN)Citizens JMP analyst Constantine Davides reiterated a Market Perform rating on Cross Country Healthcare (NASDAQ: CCRN).
Barrington Analyst forecast on CCRN
Kevin SteinkeBarrington
Barrington
$18.61
Hold
41.52%
Upside
Reiterated
03/14/25
Hold Rating Maintained for Cross Country Healthcare Amidst Profitability Decline and Pending Aya Healthcare Merger
Jefferies Analyst forecast on CCRN
Jack SlevinJefferies
Jefferies
$18.61
Hold
41.52%
Upside
Reiterated
03/12/25
We expect CCRN's proposed acquisition by Aya will close in 2025.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cross Country Healthcare

1 Month
xxx
Success Rate
1/9 ratings generated profit
11%
Average Return
-5.37%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 11.11% of your transactions generating a profit, with an average return of -5.37% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
-9.56%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -9.56% per trade.
1 Year
Kevin FischbeckBank of America Securities
Success Rate
4/9 ratings generated profit
44%
Average Return
-41.76%
reiterated a sell rating a year ago
Copying Kevin Fischbeck's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -41.76% per trade.
2 Years
xxx
Success Rate
5/9 ratings generated profit
56%
Average Return
-59.54%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of -59.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CCRN Analyst Recommendation Trends

Rating
Dec 24
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
1
1
0
0
0
Hold
11
11
14
9
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
12
14
9
13
In the current month, CCRN has received 0 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. CCRN average Analyst price target in the past 3 months is 18.08.
Each month's total comprises the sum of three months' worth of ratings.

CCRN Financial Forecast

CCRN Earnings Forecast

Next quarter’s earnings estimate for CCRN is $0.07 with a range of $0.03 to $0.12. The previous quarter’s EPS was $0.06. CCRN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CCRN has Outperformed its overall industry.
Next quarter’s earnings estimate for CCRN is $0.07 with a range of $0.03 to $0.12. The previous quarter’s EPS was $0.06. CCRN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CCRN has Outperformed its overall industry.

CCRN Sales Forecast

Next quarter’s sales forecast for CCRN is $297.68M with a range of $283.32M to $313.80M. The previous quarter’s sales results were $293.41M. CCRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CCRN has Outperformed its overall industry.
Next quarter’s sales forecast for CCRN is $297.68M with a range of $283.32M to $313.80M. The previous quarter’s sales results were $293.41M. CCRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CCRN has Outperformed its overall industry.

CCRN Stock Forecast FAQ

What is CCRN’s average 12-month price target, according to analysts?
Based on analyst ratings, Cross Country Healthcare’s 12-month average price target is 18.08.
    What is CCRN’s upside potential, based on the analysts’ average price target?
    Cross Country Healthcare has 37.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CCRN a Buy, Sell or Hold?
          Cross Country Healthcare has a consensus rating of Hold which is based on 0 buy ratings, 8 hold ratings and 0 sell ratings.
            What is Cross Country Healthcare’s price target?
            The average price target for Cross Country Healthcare is 18.08. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $18.61 ,the lowest forecast is $16.50. The average price target represents 37.49% Increase from the current price of $13.15.
              What do analysts say about Cross Country Healthcare?
              Cross Country Healthcare’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of CCRN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis